About Hyclone Life Sciences Solutions India Private Limited
Data last updated:
Hyclone Life Sciences Solutions India Private Limited is a private limited company based in Bangalore, Karnataka, India, a subsidiary of Pall Filtration Pte Ltd. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 01 August 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24304KA2019PTC126720. Its GSTIN is 29AAECH9985L1ZK (Karnataka). The company holds 8 GST registrations, of which 7 are active.
The company has an authorised share capital of ₹245 Cr and a paid-up capital of ₹235.16 Cr. It is led by directors including Satya Prasad Udandravu and James Benjamin.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Bangalore, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹539.19 Cr, a decline of 13% compared to the previous year. For the same year it recorded a net profit of ₹57.52 Cr (net margin 10.7%) and EBITDA of ₹107.53 Cr (EBITDA margin 19.9%). Revenue has grown at a compounded annual rate (CAGR) of 23% over three years and 34% over five years.
The company has about 496 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Cytiva. The company has 1 deal on record (1 secondary share transfer); the latest was in March 2020. Its 10 peer companies in the Pharma industry (Contract Research) are compared by revenue, 5 larger and 5 smaller; the largest is Ra Chem Pharma Limited with revenue of ₹621.32 Cr. The company has 15 MSME Form 1 returns on record between 2020 and 2023, listing 146 overdue payments to 21 micro and small suppliers.
For more details, the company can be reached via its website cytivalifesciences.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressGalileo John F Welch Technology Centre 122 Epip Zone Phase II Hoodi Village White, Field Road, Bangalore, Karnataka, India – 560066
- IndustryLife Sciences, Biotechnology
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Hyclone Life Sciences Solutions India Private Limited
The main business activity of Hyclone Life Sciences Solutions India is professional, scientific and technical. In detail, this covers other professional, scientific and technical activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Hyclone Life Sciences Solutions India Private Limited FY 2025 filings available
Hyclone Life Sciences Solutions India Private Limited reported revenue of ₹539.19 Cr (down 13% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Hyclone Life Sciences Solutions India Private Limited
Revenue fell 13% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 34%. EBITDA fell 32% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Hyclone Life Sciences Solutions India Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹107.53 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹57.52 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Hyclone Life Sciences Solutions India Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 19.9% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 10.7% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Hyclone Life Sciences Solutions India are in the company report.
Financial statements from FY 2020
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Contract Research). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Ra Chem Pharma Limited | ₹621.32 Cr (FY 2021) | •••• | •••• | 15.0% | •••• | Hyderabad, Telangana, India |
| Veeda Clinical Research Limited | ₹621.14 Cr (FY 2025) | •••• | •••• | 52.0% | •••• | Ahmedabad, Gujarat, India |
| Zoetis Pharmaceutical Research Private Limited | ₹595.44 Cr (FY 2025) | •••• | •••• | 28.0% | •••• | Mumbai, Maharashtra, India |
| Jubilant Biosys Limited | ₹562.86 Cr (FY 2023) | •••• | •••• | 16.0% | •••• | New Delhi, Delhi, India |
| Graviti Pharmaceuticals Private Limited | ₹543.75 Cr (FY 2025) | •••• | •••• | 17.0% | •••• | Hyderabad, Telangana, India |
| Hyclone Life Sciences Solutions India Private Limited this company | ₹539.19 Cr (FY 2025) | •••• | •••• | -13.0% | •••• | Bangalore, Karnataka, India |
| Fortrea Development India Private Limited | ₹535.42 Cr (FY 2025) | •••• | •••• | 3.0% | •••• | Bangalore, Karnataka, India |
| TCG Lifesciences Private Limited | ₹482.95 Cr (FY 2025) | •••• | •••• | -11.0% | •••• | Kolkata, West Bengal, India |
| PPD Pharmaceutical Development India Private Limited | ₹457.7 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | Mumbai, Maharashtra, India |
| Biophore India Pharmaceuticals Private Limited | ₹457 Cr (FY 2025) | •••• | •••• | 18.0% | •••• | Hyderabad, Telangana, India |
| Axis Clinicals Limited | ₹386.63 Cr (FY 2025) | •••• | •••• | -6.0% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Hyclone Life Sciences Solutions India by revenue in the Pharma industry (Contract Research), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India Private Limited is audited by S.R. BATLIBOI & ASSOCIATES LLP for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| S.R. BATLIBOI & ASSOCIATES LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors and KMP of Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India Private Limited currently reports 4 directors and 1 key managerial person. 9 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Satya Prasad Udandravu Also directs: Cytiva India Private Limited | Director | 14 Jun 2022 | 4 Years 3 Months | Current |
| James Benjamin | Director | 31 Mar 2020 | 6 Years 6 Months | Current |
| Ramakrishna Panicker Manoj Kumar Also directs: Cytiva India Private Limited | Director | 05 Jun 2024 | 2 Years 4 Months | Current |
| Amol Laxman Kulkarni | Company Secretary | 06 Mar 2020 | 6 Years 7 Months | Current |
| Balasubramanian Narayanan Iyer | Director | 12 Mar 2025 | 1 Years 6 Months | Current |
Ownership and Shareholding of Hyclone Life Sciences Solutions India Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India Private Limited has 1 deal on record (1 secondary share transfer); the latest was in March 2020.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2020 | Secondary share transfer | Undisclosed | Buyer: Pall Filtration Pte Ltd, Pall Filtration Pte Ltd & Pall Corporation Seller: Wipro Ge Healthcare Private Limited , General Electric Company, Wipro Enterprises Private Limited , an individual |
Full deal history
All 1 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
MSME Payment Delays by Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India Private Limited has 15 MSME Form 1 returns on record between 2020 and 2023, listing 146 overdue payments to 21 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 21)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Systech Services Limited | •••• | •••• | •••• |
| Pooja Lab Equipments | •••• | •••• | •••• |
| Imaginarium Rapid Private Limited | •••• | •••• | •••• |
| Transcal | •••• | •••• | •••• |
| Leistung Solutions | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 15 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India operates one associated brand: Cytiva. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Life science software and research products are provided online. | cytivalifesciences.com |
Employees and EPFO Compliance at Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India Private Limited has a workforce of 496 employees as of Apr 08, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
News related to Hyclone Life Sciences Solutions India Private Limited
Recent Activity on Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India Private Limited has 14 board changes on record since 2020: 5 appointments and 9 cessations. The latest: Balasubramanian Narayanan Iyer ceased to be Additional Director on 29 Sep 2025.
5 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Hyclone Life Sciences Solutions India Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Hyclone Life Sciences Solutions India Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India has 8 GST registrations: 7 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAECH9985L1ZK | Karnataka | Active | 31 Aug 2019 |
| 29AAECH9985L2ZJ | Karnataka | Active | 28 Feb 2025 |
| 24AAECH9985L1ZU | Gujarat | Active | 08 Nov 2019 |
| 36AAECH9985L1ZP | Telangana | Active | 26 Nov 2019 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Hyclone Life Sciences Solutions India Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hyclone Life Sciences Solutions India Private Limited
Hyclone Life Sciences Solutions India is an active private limited company based in Bangalore, Karnataka, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 01 August 2019 (7+ years old) and is registered under CIN U24304KA2019PTC126720.
Hyclone Life Sciences Solutions India reported revenue of ₹539.19 Cr for FY 2025 (down 13% YoY).
Hyclone Life Sciences Solutions India has 5 current directors and KMP:
- Satya Prasad Udandravu - Director
- James Benjamin - Director
- Ramakrishna Panicker Manoj Kumar - Director
- Balasubramanian Narayanan Iyer - Director
- Amol Laxman Kulkarni - Company Secretary
Hyclone Life Sciences Solutions India reported a net profit of ₹57.52 Cr (net margin 10.7%) and EBITDA of ₹107.53 Cr (EBITDA margin 19.9%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Hyclone Life Sciences Solutions India is 23% over three years and 34% over five years. In the latest year (FY 2025) revenue fell 13%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Hyclone Life Sciences Solutions India is 29AAECH9985L1ZK, registered in Karnataka. The company has 8 GST registrations in all, of which 7 are active and 1 is cancelled or inactive. Other active GSTINs include 29AAECH9985L2ZJ (Karnataka), 24AAECH9985L1ZU (Gujarat), 36AAECH9985L1ZP (Telangana).
The CIN (Corporate Identification Number) of Hyclone Life Sciences Solutions India is U24304KA2019PTC126720. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Hyclone Life Sciences Solutions India was incorporated on 01 August 2019, making it 7+ years old. It is registered with the Registrar of Companies, Bangalore.
Hyclone Life Sciences Solutions India has 1 deal on record (1 secondary share transfer); the latest was in March 2020.
The peers of Hyclone Life Sciences Solutions India by revenue are Ra Chem Pharma Limited, Veeda Clinical Research Limited, Zoetis Pharmaceutical Research Private Limited, Jubilant Biosys Limited, Graviti Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Contract Research).
Balasubramanian Narayanan Iyer ceased to be Additional Director on 29 Sep 2025. Balasubramanian Narayanan Iyer was appointed as Director on 12 Mar 2025. Ramakrishna Panicker Manoj Kumar ceased to be Additional Director on 29 Sep 2024. Hyclone Life Sciences Solutions India has 14 board changes on record in total.
Hyclone Life Sciences Solutions India has 15 MSME Form 1 returns on record between 2020 and 2023, listing 146 overdue payments to 21 micro and small suppliers. The latest return was filed on 28 Aug 2023.